rais ew pt
refin tavr market model reflect heighten tavr adopt
heel favor low risk trial result label
restrict use tavr younger patient bicuspid morpholog
increas cannib surgeri begin rais
princip dcf base ew price target driven
base busi inclus tavr termin valu associ
profit stem mitral/tricuspid adjac circa
ew revenu estim upwardli
princip base stronger outlook tavr market also
influenc fx higher expect critic care
 ep estim rise
 part due higher revenu also recent
announc reduct anticip tax rate
adjust us preval pool model note model predic
preval popul address aortic stenosi patient
circa associ incid period
expect us tavr market show compound-annual-growth-rate surgic
case amongst yoa declin tavr unit increas
due high incid amongst elderli yoa fast growth
rate demograph aortic stenosi preval model
doesnt reflect us preval pool deplet despit aortic valv
replac amongst yoa rise around tavr
around tavr
valuat risk revis price target arriv dcf end
deriv valu base busi inclus tavr
discount rate termin growth assign termin
valu mitral/tricuspid revenu oper profit
discount rate termin growth price target equat
ep estim risk thesi includ over-estim aortic
stenosi mitral tricuspid preval pool greater anticip friction
regard product adopt higher expect competit and/or price
continu pg
tr target
ep exclud amort begin
histor trend savr suggest tavr larg market expand
exhibit present case count adjust feder hospit savr tavr deriv
nation inpati sampl age group data indic base compani
commentari larg case tavr mainli market
expand tavr open treatment option elderli patient offer surgeri
princip due reluct surgeon oper patient yoa note period
examin exhibit savr amongst patient yoa remain steadi despit explos
growth tavr
exhibit us savr tavr aovr procedur scale fed hospit
nation inpati sampl ni healthcar util project hcup agenc healthcar research
prior note link estim current surgic popul age around
around patient would suitabl substitut tavr tavr plu
stage pci either didnt requir aneurysm repair multipl valv procedur extens
page
savr savr tavr tavr aortiv valv replac aovr aovr edward lifesci corpor
surgic revascular applic estim around bicuspid valv
morpholog havent studi random tavr versu surgeri clinic trial
low risk trial bicuspid label lack contra-ind import
histor object surgic risk score via st score hasnt restrict adopt tavr amongst
elderli patient especi year old earli well fda grant
intermedi risk label implant tavr patient st score
high risk cut-off said guess good surgic candid mainli age
part retain along surgic path low risk st random data
avail similarli preval bicuspid valv morpholog rise dramat age
link earlier gener tavr devic appear unaccept high rate
moder plu pvl high new perman pacemak requir elev risk annulu
ruptur final tavr versu savr durabl question remain somewhat unresolv
relev younger patient
revisit deplet preval pool model made follow assumpt firstli
assum tavr low risk trial least show equival surgeri first data read-out
march make tavr strong patient prefer surgic candid
yoa secondli base review literatur see instanc perlman et al jacc intv
yoon et al jacc tavr outcom patient bicuspid valv
seem improv suffici new gener devic us assum fda
restrict tavr bicuspid use grant risk label thirdli make assumpt
recent design iter greater sensit treatment sub-clin leaflet thrombosi make
like neg durabl signal wont preclud use tavr amongst elig tissu
valv gener yoa low-risk label grant esp patient yoa
preval incid sever aortic stenosi patient meet current criteria intervent
age specif preval estim deriv review epidemiolog literatur
well count inpati nation inpati sampl diagnosi aortic
valv diseas suffer symptomat heart-failur scale outpati
hospit given year link line inquiri gener concord
suggest around preval address us patient dissimilar
suggest ew specif analysi includ symptomat patient higher risk
asymptomat patient meet current guidelin intervent dont includ
lower risk asymptomat patient part studi on-going earli tavr trial
patient moder aortic stenosi advanc heart failur studi tavr
exhibit show estim nativ popul patient sever aortic stenosi
symptomat asymptomat person age schemat assign age specif
preval rate anticip demograph shift us popul per censu estim assign
mortal rate deriv age specif incid assum preval patient
page
symptomat elig intervent circa exhibit posit address
aortic stenosi patient analysi suggest elig popul yoa
overal incid around patient due age popul may
rise importantli grow incid burden stabil deplet preval pool
adjust implant shown despit strong anticip growth aortic valv replac
amongst yoa compound-annual-growth-rate
exhibit us natur preval incid
deplet preval model group
deplet preval pool model adjust annual start preval pool downward aortic
valv replac death amongst untreat patient adjust upward newli incid
patient imput natur occur popul exhibit exhibit show key
assumpt aortic valv replac penetr express deplet preval pool
incid cohort well savr tavr mix exhibit doesnt shown deplet preval
pool patient yoa rel insignific tavr market model
exhibit show savr histor perform patient yoa
page
 popul yoa popul yoa popul yoa rate rate rate qualifi rate untreat rate untreat rate untreat edward lifesci corpor
exhibit deplet preval model group
nation inpati sampl ni healthcar util project hcup agenc healthcar research
patient yoa exhibit show overal aortic valv replac penetr express
deplet preval pool rise rel non-hero
assumpt given lethal condit avail minim invas cur
treatment express percent incid popul penetr rise
tavr percent aortic valv replac mix rise
acceler begin releas risk trial result weve
steepen declin surgeri group rel prior model iter surgic volum
declin surgic volum declin
cohort percentag declin well current surgic patient
suitabl tavr basi requir aneurysm repair multipl valv replacement/repair
import age cohort yoa model show aortic replac penetr
express percent deplet preval pool rise
case growth absorb tavr express percent incid cohort
penetr rise tavr mix rise estim
given reluct surgeon perform complic open heart procedur inclus multipl
valv replacements/repair patient yoa dont feel unreason presum
tavr remain overwhelm treatment choic amongst elderli even minor
case work left undon overal surgic volum age group declin
period importantli deplet preval pool actual increas key
group despit strong growth number treat
growth incid due demograph lift
page
yoabegin preval aov patient rate untreat untreat preval deplet aov yoabegin preval aov patient rate untreat untreat preval deplet aov corpor
exhibit show tavr model unit growth overwhelm account
tune patient yoa
exhibit tavr unit
us market ww
exhibit show us savr tavr annual total patient yoa well us ww
revenu assumpt tavr show aortic valv treatment rate grow
period doesnt seem unreason given lethal diseas
avail minim invas cur altern surgeri low treatment penetr
amongst domin elderli group rel fast underli growth rate
yoa popul importantli note preval pool remain stabl
due grow incid rate driven demograph lift amongst elderli
expect unit compound-annual-growth-rate us savr case patient yoa
undoubtedli put pressur ew surgic busi strong asp uplift less invas surgic
product well complic construct younger patient aortic valv
aneurysm repair like keep busi reason stabl model unit compound-annual-growth-rate tavr
time frame us revenu market show compound-annual-growth-rate due modest price declin
importantli sentiment toward ew us revenu growth assumpt period
rais somewhat part due greater previous model surgic
cannib follow releas risk result also somewhat higher assum
recruit elderli patient heretofor left untreat case follow
intermedi risk data world-wid basi assum market approxim
roughli in-lin cite ew
nation inpati sampl ni healthcar util project hcup agenc healthcar research
page
growth tavr tavr tavr tavr preval ao deplet ao tavr asp tavr revenu market revenu edward lifesci corpor
page
million except per share surgeri expens inc interest incom adjust analysisgross sg sale sale cc cc ex cc incl cc incl cardioband vasc forma corpor
edward lifesci corp focus technolog treat structur heart diseas
critic ill patient design develop manufactur market product treat cardiovascular
diseas product technolog categor three area surgic heart valv therapi
transcathet heart valv critic surgic heart valv therapi portfolio includ
tissu heart valv heart valv repair product surgic replac repair patient
heart valv transcathet heart valv portfolio includ technolog design treat heart
valv diseas use catheter-bas approach oppos open surgic techniqu critic
portfolio product includ pulmonari arteri cathet dispos pressur transduc
advanc monitor system found mile lowel edward
headquart irvin ca
remain buy rate ew given confid tavr market reach
address us patient link inclus high risk asymptomat patient fall
within guidelin today said market growth tune depend
upon recruit elderli patient larg untreat prior advent tavr rather
surgic cannib link potenti growth uneven quarterli
basi addit confid long term valu creation opportun ew especi
given larg size mitral address symptomat us patient link tricuspid
address symptomat us patient link opportun
valuat risk
price target arriv dcf end deriv valu base
busi inclus tavr discount rate termin growth assign
termin valu mitral/tricuspid revenu oper profit discount rate
termin growth price target equat ep estim risk
thesi includ over-estim aortic stenosi mitral tricuspid preval pool greater
anticip friction regard product adopt higher expect competit and/or price
compani mention note
bruce nudel herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
